ライフサイエンスコーパス: glycaemic

1 uppressed the fetal femoral vasoconstrictor, glycaemic and lactate acidaemic responses during hypoxia

2 Glycaemic and lipid factors may play a vasoconstrictive

3 uded changes in uric acid concentrations and glycaemic and lipid variables.

4 Here we analyse glycaemic and metabolic control, cardiovascular risk, me

5 Rapid glycaemic change in patients with uncontrolled diabetes

6 on was the same when adjusted for centre and glycaemic control (0.55 [0.30-1.03], p = 0.06).

7 type 2 diabetes mellitus who had inadequate glycaemic control (glycosylated haemoglobin [HbA(1c)] 7.

8 es in blood pressure, total cholesterol, and glycaemic control (haemoglobin A1c) after 2 years.

9 .0-12.6], p=0.0004), mainly through improved glycaemic control (HbA1c <7.0% [53 mmol/mol] in 45 [75%]

10 They were eligible when they had suboptimum glycaemic control (HbA1c 7.1-11.0% [54-97 mmol/mol]) des

11 8 years) with type 2 diabetes and inadequate glycaemic control (HbA1c 8-12% [64-108 mmol/mol]) despit

12 Associations between glycaemic control (HbA1c), episodes of diabetic ketoacid

13 a 3 month run-in to optimise risk factor and glycaemic control (single-blind placebo in the final mon

14 diabetes overall and by different levels of glycaemic control and albuminuria.

15 n to reduce the risk of diabetes and improve glycaemic control and blood lipids in patients with diab

16 or factor that contributes to long-term poor glycaemic control and diabetic ketoacidosis in this age

17 Poor glycaemic control and impaired renal function substantia

18 The inferior glycaemic control and increased risk of hypoglycaemia wi

19 dies have characterised the relation between glycaemic control and infectious disease, which we discu

20 c modulator of hGPR40, demonstrates improved glycaemic control and low hypoglycaemic risk in diabetic

21 iabetes, there are improvements in long-term glycaemic control and psychological distress but not in

22 e and liraglutide have been shown to improve glycaemic control and reduce bodyweight in patients with

23 in delivery is a promising option to improve glycaemic control and reduce the risk of hypoglycaemia.

24 us insulin therapy has been shown to improve glycaemic control and reduce the risk of long-term compl

25 peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with typ

26 ith type 1 diabetes increased with worsening glycaemic control and renal complications.

27 fects on cardiovascular risk factors such as glycaemic control and reverse cholesterol transport.

28 owever, many patients do not achieve optimum glycaemic control and therefore new therapies are necess

29 tter treatment approaches for achieving good glycaemic control are badly needed.

30 ment of depression as well as improvement in glycaemic control as a marker for subsequent diabetes ou

31 ion (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they ta

32 Strict glycaemic control can decrease development and progressi

33 tor agonist treatment, resulting in improved glycaemic control compared with its components given alo

34 of vascular risk factors and optimisation of glycaemic control could have therapeutic benefit.

35 ients with type 2 diabetes mellitus and poor glycaemic control despite insulin therapy, with or witho

36 Patients with type 2 diabetes who had poor glycaemic control despite multiple daily injections with

37 Mean HbA1c was used to assess glycaemic control during follow-up.

38 Intensive glycaemic control had no significant effect on events of

39 At 6 months, glycaemic control had worsened in the control group (mea

40 Intensive insulin therapy with tight glycaemic control has been advocated for improving outco

41 ct to insulin therapy in IDDM, might improve glycaemic control in adolescents; we investigated the ef

42 a do not support use of metformin to improve glycaemic control in adults with long-standing type 1 di

43 that severe periodontitis adversely affects glycaemic control in diabetes and glycaemia in non-diabe

44 diagnostic assays for the long-term mark of glycaemic control in diabetes.

45 chological problems are associated with poor glycaemic control in diabetes.

46 Intensive treatment to achieve good glycaemic control in diabetic patients is limited by a h

47 s suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabet

48 lts of randomised controlled trials of tight glycaemic control in hospital inpatients might vary with

49 Good glycaemic control in insulin-dependent diabetes mellitus

50 und, has been shown to significantly improve glycaemic control in large-scale clinical trials, and sh

51 Poorer glycaemic control in participants with known diabetes wa

52 gest that sacubitril/valsartan might enhance glycaemic control in patients with diabetes and HFrEF.

53 sing adjunct treatment to insulin to improve glycaemic control in patients with inadequately controll

54 Whether these actions contribute to improved glycaemic control in patients with insulin resistance wa

55 view aims to appraise the evidence for tight glycaemic control in patients with neurological injury.

56 Optimum glycaemic control in patients with type 2 diabetes is im

57 TERPRETATION: TAK-875 significantly improved glycaemic control in patients with type 2 diabetes with

58 educe hepatic fat content (HFC) and increase glycaemic control in pre-diabetic patients with non-alco

59 europathy caused by an abrupt improvement in glycaemic control in the setting of chronic hyperglycaem

60 The evidence for improved glycaemic control in the treatment of depression by use

61 Effective glycaemic control in type 1 diabetes mellitus usually re

62 s to assess their effectiveness in improving glycaemic control in type 2 diabetes.

63 rent clinical use in improving post-prandial glycaemic control in type 2 diabetics.

64 n this age group, and evidence suggests that glycaemic control is often neglected.

65 However, continued monitoring of glycaemic control is warranted because of potential rela

66 Tight glycaemic control may result in hypoglycaemia, which in

67 The main outcome was long-term glycaemic control measured by percentage of glycated hae

68 INTERPRETATION: Our findings show that glycaemic control measured by time in the glucose range

69 Evidence suggests that better glycaemic control might reduce infection risk, but furth

70 se prandial insulin intensification provides glycaemic control non-inferior to a full basal-bolus reg

71 The deterioration in glycaemic control observed in patients aged 10-20 years

72 tic subtype defines treatment, with improved glycaemic control on sulfonylurea treatment for most pat

73 No therapy altered glycaemic control or body weight.

74 Tight glycaemic control reduces microvascular complications in

75 or the treatment of type 2 diabetes, optimum glycaemic control remains challenging for many patients

76 Intensive glycaemic control resulted in a 17% reduction in events

77 Overall, intensive compared with standard glycaemic control significantly reduces coronary events

78 Target-based intensive glycaemic control strategies (RR 1.00, 95% CI 0.88-1.13;

79 ess of a continuous, day-and-night automated glycaemic control system using insulin and glucagon has

80 were randomly assigned to receive intensive glycaemic control targeting HbA(1c) to less than 6.0% (4

81 There is more uncertainty about appropriate glycaemic control targets in this age group, and evidenc

82 ovided significantly greater improvements in glycaemic control than did exenatide twice a day, and wa

83 ed in a significantly greater improvement in glycaemic control than did glargine and represents a new

84 essation is associated with deterioration in glycaemic control that lasts for 3 years and is unrelate

85 lbumin are markers of short-term (2-4 weeks) glycaemic control that might add complementary prognosti

86 l prescription of blood pressure, lipid, and glycaemic control treatments for adults with type 2 diab

87 Worse glycaemic control was associated with increased risk of

88 uration of diabetes in late midlife and poor glycaemic control were associated with accelerated cogni

89 rmin (>/=1500 mg per day) and had inadequate glycaemic control were randomly assigned to receive one

90 l tests, vibration perception-threshold, and glycaemic control were unchanged.

91 rofile of longer than 42 h, provided similar glycaemic control when injected three times a week (IDeg

92 ype 1 diabetes because it provides effective glycaemic control while lowering the risk of nocturnal h

93 preparations has the potential for improving glycaemic control with a high degree of patient acceptan

94 th type 2 diabetes who do not achieve target glycaemic control with conventional insulin treatment, a

95 ts with type 2 diabetes who had insufficient glycaemic control with diet and exercise alone.

96 e 2 diabetes in patients who have inadequate glycaemic control with metformin alone.

97 type 2 diabetes who did not achieve adequate glycaemic control with metformin alone.

98 ged 18 years and older, who had insufficient glycaemic control with metformin either alone or in comb

99 n for patients who do not achieve sufficient glycaemic control with metformin therapy.

100 apagliflozin in patients who have inadequate glycaemic control with metformin.

101 ients with type 2 diabetes mellitus improved glycaemic control without hypoglycaemia risk.

102 ncentrations to less than 8 mmol/L (moderate glycaemic control), while avoiding mild hypoglycaemia (<

103 es, including fear of hypoglycaemia, loss of glycaemic control, and inadequate knowledge around exerc

104 ther owners experience facilitated tightened glycaemic control, and wider psychosocial benefits.

105 otential value of alert dogs, for increasing glycaemic control, client independence and consequent qu

106 t, adverse effects of periodontal disease on glycaemic control, diabetes complications, and developme

107 n treatment is thought to contribute to poor glycaemic control, diabetic ketoacidosis, and brittle di

108 characterized by excess adiposity, impaired glycaemic control, dyslipidaemia and moderate hypertensi

109 enhanced prevention measures preoperatively (glycaemic control, skin decontamination, decolonisation,

110 rticipants, their age, duration of diabetes, glycaemic control, type of psychological therapy, its mo

111 Good glycaemic control, which reduces long-term diabetes comp

112 once weekly exenatide led to improvements in glycaemic control, with greater reductions noted with li

113 once weekly exenatide led to improvements in glycaemic control, with greater reductions noted with li

114 ion within 8 weeks of a large improvement in glycaemic control-specified as a decrease in glycosylate

115 CD diagnosis does not impact on T1DM glycaemic control.

116 most effective treatment for weight loss and glycaemic control.

117 ere is little evidence that it may influence glycaemic control.

118 etary means for type 2 diabetics to exercise glycaemic control.

119 HbA(1c) of <7% and 37% had very poor (>/=9%) glycaemic control.

120 o glucose monitoring is required for tighter glycaemic control.

121 ntervention soon after diagnosis can improve glycaemic control.

122 nd brain volume of intensive versus standard glycaemic control.

123 increased with renal complications and poor glycaemic control.

124 lyses show small to moderate improvements in glycaemic control.

125 -cell mass and insulin content, and improves glycaemic control.

126 es is dependent on both disease duration and glycaemic control.

127 t-transplant diabetes; establish the role of glycaemic control; and assess the role of new diabetic t

128 se of the high levels of glycaemia and rapid glycaemic deterioration noted in this population.

129 in advance of the development of obesity or glycaemic dysregulation.

130 xposure to HFD well in advance of obesity or glycaemic dysregulation.

131 We aimed to compare blood pressure and glycaemic effects of the SGLT2 inhibitor dapagliflozin w

132 Glycaemic efficacy of Technosphere inhaled insulin is lo

133 In patients with type 1 or type 2 diabetes, glycaemic exposure assessed as HbA1c correlates strongly

134 tment decisions for achieving individualised glycaemic goals with minimal risk in this important popu

135 d profile, body composition, and fitness and glycaemic goals.

136 o indicate potential for improvements in non-glycaemic health outcomes from CGM use.

137 arbohydrate digestion to make foods of lower glycaemic impact.

138 Lowest glycaemic index (54.58) and the highest sensory scores (

139 ture, in vitro starch digestibility, in vivo glycaemic index (GI) and sensorial properties of biscuit

140 Clinical studies suggest a role for dietary glycaemic index (GI) in bodyweight regulation and diabet

141 enhanced nutritional characteristics and low glycaemic index (GI).

142 Carbohydrates with high glycaemic index are proposed to promote the development

143 Dietary carbohydrates with a high glycaemic index cause a high postprandial glucose and in

144 MBB, WBB, OSB and MSB had a glycaemic index of 75+/-4, 71+/-5, 68+/-5 and 65+/-4, re

145 This study examined whether the glycaemic index of dietary carbohydrates is a determinan

146 PS) in reducing the starch digestibility and glycaemic index of noodles was investigated.

147 serum HDL-cholesterol concentration and the glycaemic index of the diet for both men (regression coe

148 Thus, the glycaemic index of the diet is a stronger predictor than

149 s-sectional study of middle-aged adults, the glycaemic index of the diet was the only dietary variabl

150 The estimated glycaemic index was higher in breads with higher hydrati

151 activity and reduced phytic acid content and glycaemic index, although a slight decrease in in vitro

152 ics, including the type of carbohydrate, the glycaemic index, and fat intake.

153 dietary patterns such as Mediterranean, low glycaemic index, moderately low carbohydrate, and vegeta

154 urdough fermentation with a presumable lower glycaemic index.

155 gnitude of the femoral vasoconstriction, the glycaemic, lactacidaemic and acidaemic responses and the

156 ated with the level of glycated haemoglobin, glycaemic level, and time of disease onset.

157 21 and 56) to determine the level of GI and glycaemic load (GL).

158 ntervention group, including reduced dietary glycaemic load, gestational weight gain, and maternal su

159 Compared with standard care, glycaemic lowering by various drugs or strategies might

160 efficacy of continuous, multiday, automated glycaemic management has not been tested in outpatient s

161 he long-term benefits and risks of automated glycaemic management with a bihormonal bionic pancreas.

162 generation of biofunctional ingredients for glycaemic management.

163 hat can be prevented or delayed by intensive glycaemic management.

164 exenatide and dapagliflozin improved various glycaemic measures and cardiovascular risk factors in pa

165 e converted systematically between different glycaemic metrics.

166 We aimed to assess glycaemic outcomes when switching from multiple daily in

167 -0.846), and after additional adjustment for glycaemic parameters (model-2, OR: 0.670, 95%CI: 0.511-0

168 r of the MALT1 gene, involved in insulin and glycaemic pathways, and related to taurocholate levels i

169 nnel abnormality can result in a fluctuating glycaemic phenotype.

170 auses of monogenic diabetes helps understand glycaemic regulation in humans.

171 Novel approaches to glycaemic regulation include use of inhibitors of the so

172 ng sequentially numbered sealed envelopes to glycaemic regulation with a bihormonal bionic pancreas o

173 icipant weight, was able to achieve superior glycaemic regulation without the need for carbohydrate c

174 icipant weight, was able to achieve superior glycaemic regulation without the need for carbohydrate c

175 A similar trend was observed for glycaemic response in vivo.

176 ns could be an innovative route to alter the glycaemic response of carbohydrate-rich foods.

177 Glycaemic response to metformin is heritable, thus glyca

178 mic response to metformin is heritable, thus glycaemic response to metformin is, in part, intrinsic t

179 We aimed to establish the heritability of glycaemic response to metformin using the genome-wide co

180 The heritability of glycaemic response to metformin varied by response pheno

181 whom 2085 had enough clinical data to define glycaemic response to metformin.

182 stimate heritability for four definitions of glycaemic response to metformin: absolute reduction in H

183 We aimed to see whether the glycaemic response to the sulphonylurea gliclazide and t

184 sed in the treatment of type 2 diabetes, but glycaemic response to this drug is highly variable.

185 ration conditions, is a major determinant of glycaemic response.

186 antagonistic or synergic effect on predicted glycaemic response.

187 and steamed bread was healthier in terms of glycaemic response.

188 d to an antagonistic effect on the predicted glycaemic response.

189 y diminished the femoral vasoconstrictor and glycaemic responses to hypoxaemia, and attenuated the in

190 sed to quantify the effect of previous (DPP) glycaemic status on risk of later (DPPOS) diabetes and n

191 insoluble fibre, essential amino acids, low glycaemic sugars, resistant to thermal food processing a

192 Individualised glycaemic target levels are achievable with vildagliptin

193 atment option for patients unable to achieve glycaemic targets with conventional insulin treatment.

194 ) [HbA(1c)] of <6.0%) or standard (7.0-7.9%) glycaemic therapy.

195 cases, 76 344 non-cases; five studies), and glycaemic traits (concentrations of fasting glucose, 2-h

196 ce for an association between depression and glycaemic traits (eg, glucose, insulin, insulin sensitiv

197 otyped studies of CAD, MI, diabetes, lipids, glycaemic traits and adiposity to obtain unconfounded es

198 Glycaemic traits such as fasting and post-challenge gluc

199 endelian randomisation-derived estimates for glycaemic traits were not significant (p>0.25).

200 D concentration with type 2 diabetes and the glycaemic traits, and compared them with that from a met

201 recent advances in the genetic aetiology of glycaemic traits, and the resulting biological insights.

202 to the discovery of over 97 loci influencing glycaemic traits.

203 blood-based metabolic traits, in addition to glycaemic values, could optimise estimation of diabetes

204 flexibility, and a somewhat higher degree of glycaemic variability and hypoglycaemia when compared to

205 h-risk state for diabetes that is defined by glycaemic variables that are higher than normal, but low